154 related articles for article (PubMed ID: 38605297)
1. Mitotic gene regulation by the N-MYC-WDR5-PDPK1 nexus.
Streeter SA; Williams AG; Evans JR; Wang J; Guarnaccia AD; Florian AC; Al-Tobasei R; Liu Q; Tansey WP; Weissmiller AM
BMC Genomics; 2024 Apr; 25(1):360. PubMed ID: 38605297
[TBL] [Abstract][Full Text] [Related]
2. WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma.
Sun Y; Bell JL; Carter D; Gherardi S; Poulos RC; Milazzo G; Wong JW; Al-Awar R; Tee AE; Liu PY; Liu B; Atmadibrata B; Wong M; Trahair T; Zhao Q; Shohet JM; Haupt Y; Schulte JH; Brown PJ; Arrowsmith CH; Vedadi M; MacKenzie KL; Hüttelmaier S; Perini G; Marshall GM; Braithwaite A; Liu T
Cancer Res; 2015 Dec; 75(23):5143-54. PubMed ID: 26471359
[TBL] [Abstract][Full Text] [Related]
3. Impact of WIN site inhibitor on the WDR5 interactome.
Guarnaccia AD; Rose KL; Wang J; Zhao B; Popay TM; Wang CE; Guerrazzi K; Hill S; Woodley CM; Hansen TJ; Lorey SL; Shaw JG; Payne WG; Weissmiller AM; Olejniczak ET; Fesik SW; Liu Q; Tansey WP
Cell Rep; 2021 Jan; 34(3):108636. PubMed ID: 33472061
[TBL] [Abstract][Full Text] [Related]
4. WDR5 facilitates recruitment of N-MYC to conserved WDR5 gene targets in neuroblastoma cell lines.
Bumpous LA; Moe KC; Wang J; Carver LA; Williams AG; Romer AS; Scobee JD; Maxwell JN; Jones CA; Chung DH; Tansey WP; Liu Q; Weissmiller AM
Oncogenesis; 2023 Jun; 12(1):32. PubMed ID: 37336886
[TBL] [Abstract][Full Text] [Related]
5. Discovery, evaluation and mechanism study of WDR5-targeted small molecular inhibitors for neuroblastoma.
Han QL; Zhang XL; Ren PX; Mei LH; Lin WH; Wang L; Cao Y; Li K; Bai F
Acta Pharmacol Sin; 2023 Apr; 44(4):877-887. PubMed ID: 36207403
[TBL] [Abstract][Full Text] [Related]
6. LncRNA AC142119.1 facilitates the progression of neuroblastoma by epigenetically initiating the transcription of MYCN.
Yang R; Liu N; Li T; Liu F; Zhang J; Zhao H; Zou L; He X
J Transl Med; 2023 Sep; 21(1):659. PubMed ID: 37741985
[TBL] [Abstract][Full Text] [Related]
7. WDR5-Myc axis promotes the progression of glioblastoma and neuroblastoma by transcriptional activating CARM1.
Wang F; Zhang J; Ke X; Peng W; Zhao G; Peng S; Xu J; Xu B; Cui H
Biochem Biophys Res Commun; 2020 Mar; 523(3):699-706. PubMed ID: 31948749
[TBL] [Abstract][Full Text] [Related]
8. Unannotated microprotein EMBOW regulates the interactome and chromatin and mitotic functions of WDR5.
Chen Y; Su H; Zhao J; Na Z; Jiang K; Bacchiocchi A; Loh KH; Halaban R; Wang Z; Cao X; Slavoff SA
Cell Rep; 2023 Sep; 42(9):113145. PubMed ID: 37725512
[TBL] [Abstract][Full Text] [Related]
9. Discovery and Structure-Based Design of Inhibitors of the WD Repeat-Containing Protein 5 (WDR5)-MYC Interaction.
Ding J; Liu L; Chiang YL; Zhao M; Liu H; Yang F; Shen L; Lin Y; Deng H; Gao J; Sage DR; West L; Llamas LA; Hao X; Kawatkar S; Li E; Jain RK; Tallarico JA; Canham SM; Wang H
J Med Chem; 2023 Jun; 66(12):8310-8323. PubMed ID: 37307526
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic MYC amplifies mitotic perturbations.
Littler S; Sloss O; Geary B; Pierce A; Whetton AD; Taylor SS
Open Biol; 2019 Aug; 9(8):190136. PubMed ID: 31455158
[TBL] [Abstract][Full Text] [Related]
11. Interaction of the oncoprotein transcription factor MYC with its chromatin cofactor WDR5 is essential for tumor maintenance.
Thomas LR; Adams CM; Wang J; Weissmiller AM; Creighton J; Lorey SL; Liu Q; Fesik SW; Eischen CM; Tansey WP
Proc Natl Acad Sci U S A; 2019 Dec; 116(50):25260-25268. PubMed ID: 31767764
[TBL] [Abstract][Full Text] [Related]
12. Interplay between MycN and c-Myc regulates radioresistance and cancer stem cell phenotype in neuroblastoma upon glutamine deprivation.
Le Grand M; Mukha A; Püschel J; Valli E; Kamili A; Vittorio O; Dubrovska A; Kavallaris M
Theranostics; 2020; 10(14):6411-6429. PubMed ID: 32483461
[TBL] [Abstract][Full Text] [Related]
13. MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas.
Huang R; Cheung NK; Vider J; Cheung IY; Gerald WL; Tickoo SK; Holland EC; Blasberg RG
FASEB J; 2011 Dec; 25(12):4138-49. PubMed ID: 21856782
[TBL] [Abstract][Full Text] [Related]
14. MLL/WDR5 Complex Regulates Kif2A Localization to Ensure Chromosome Congression and Proper Spindle Assembly during Mitosis.
Ali A; Veeranki SN; Chinchole A; Tyagi S
Dev Cell; 2017 Jun; 41(6):605-622.e7. PubMed ID: 28633016
[TBL] [Abstract][Full Text] [Related]
15. Identification and pharmacological inactivation of the MYCN gene network as a therapeutic strategy for neuroblastic tumor cells.
Chayka O; D'Acunto CW; Middleton O; Arab M; Sala A
J Biol Chem; 2015 Jan; 290(4):2198-212. PubMed ID: 25477524
[TBL] [Abstract][Full Text] [Related]
16. Binomial mitotic segregation of MYCN-carrying double minutes in neuroblastoma illustrates the role of randomness in oncogene amplification.
Lundberg G; Rosengren AH; Håkanson U; Stewénius H; Jin Y; Stewénius Y; Påhlman S; Gisselsson D
PLoS One; 2008 Aug; 3(8):e3099. PubMed ID: 18769732
[TBL] [Abstract][Full Text] [Related]
17. Phosphoinositide protein kinase PDPK1 is a crucial cell signaling mediator in multiple myeloma.
Chinen Y; Kuroda J; Shimura Y; Nagoshi H; Kiyota M; Yamamoto-Sugitani M; Mizutani S; Sakamoto N; Ri M; Kawata E; Kobayashi T; Matsumoto Y; Horiike S; Iida S; Taniwaki M
Cancer Res; 2014 Dec; 74(24):7418-29. PubMed ID: 25269480
[TBL] [Abstract][Full Text] [Related]
18. The MYC-WDR5 Nexus and Cancer.
Thomas LR; Foshage AM; Weissmiller AM; Tansey WP
Cancer Res; 2015 Oct; 75(19):4012-5. PubMed ID: 26383167
[TBL] [Abstract][Full Text] [Related]
19. Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma.
Zhai L; Balachandran A; Larkin R; Seneviratne JA; Chung SA; Lalwani A; Tsubota S; Beck D; Kadomatsu K; Beckers A; Durink K; De Preter K; Speleman F; Haber M; Norris MD; Swarbrick A; Cheung BB; Marshall GM; Carter DR
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958555
[No Abstract] [Full Text] [Related]
20. WD repeat domain 5 promotes chemoresistance and Programmed Death-Ligand 1 expression in prostate cancer.
Zhou Q; Chen X; He H; Peng S; Zhang Y; Zhang J; Cheng L; Liu S; Huang M; Xie R; Lin T; Huang J
Theranostics; 2021; 11(10):4809-4824. PubMed ID: 33754029
[No Abstract] [Full Text] [Related]
[Next] [New Search]
